Last updated: 2026-09-06 13:29:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Organon & Co. (OGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $13.78, with a market capitalization of $3.62B and a P/E ratio of 17.31. Over the past 52 weeks, its price has ranged from $5.69 to $13.79. This page covers its latest market performance, valuation, price trends and company information.
$3.62B | |
$13.76 | |
$39.48 | |
$5.69 | |
$13.77 | |
4.67M | |
2.76M | |
17.31 | |
$13.79 | |
$5.69 | |
0.50% | |
-- |
Organon & Co. (OGN) last closed at $13.77 as of 2026-09-04 23:31:00, unchanged from the previous close of $13.77.
During the latest regular trading session, OGN traded between $5.69 and $39.48, with a volume of 4.67M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Organon & Co. (OGN) moved from $13.76 to $13.78, representing a gain of 0.11% ($0.02).
The stock traded between $13.73 and $13.79 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 3.69 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 99.9%
OGN is currently trading at $13.78, placing it 99.9% of the way from its 52-week low of $5.69 to its 52-week high of $13.79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 10000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Organon & Co. (OGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.